Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Clinical Cancer Res
These peptides have not been FDA-approved as drugs, and for most of them we still lack rigorous clinical evidence for safety and efficacy
Key Products: SEP-631, an oral small-molecule negative allosteric modulator (NAM) targeting the MRGPRX2 receptor
After the 6-wk chronic ethanol feeding, the most striking difference between WT and KO mice was the complete prevention of steatosis development in KO mice
US$ 25.94
US$ 20.88
US$ 24.28
US$ 25.50
:max_bytes(150000):strip_icc()/GettyImages-2246015697-1f1c65229d9d47fbb5df86e120ce93fc.jpg)